Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models - Wikidata - awgldk - TriplyDB

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

http://www.wikidata.org/entity/Q24629814

about

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis MET: a critical player in tumorigenesis and therapeutic target Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling Gastric Cancer: New Drugs - New Strategies Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations A role for receptor tyrosine phosphatase zeta in glioma cell migration Drug development against metastasis-related genes and their pathways: A rationale for cancer therapy A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met.Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET.Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer.Epigallocatechin-3-gallate inhibits paracrine and autocrine hepatocyte growth factor/scatter factor-induced tumor cell migration and invasion.Fibroblast growth factors in cancer: therapeutic possibilities.Adenovirus expressing dual c-Met-specific shRNA exhibits potent antitumor effect through autophagic cell death accompanied by senescence-like phenotypes in glioblastoma cells Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression HGF stimulates proliferation through the HGF/c-Met pathway in nasopharyngeal carcinoma cells MET Expression in Primary and Metastatic Clear Cell Renal Cell Carcinoma: Implications of Correlative Biomarker Assessment to MET Pathway Inhibitors.Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621 Flexibility and small pockets at protein-protein interfaces: New insights into druggability.Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.Ionizing radiation in glioblastoma initiating cells.Emerging monoclonal antibody therapies for malignant gliomas.A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met Antiangiogenic therapy in brain tumors.Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth c-Met targeted therapy of cholangiocarcinoma MET as a target for treatment of chest tumors Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation An update in the use of antibodies to treat glioblastoma multiforme.Targeting the Met signaling pathway in renal cancer.Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer.The epigenetic reprogramming of poorly aggressive melanoma cells by a metastatic microenvironment.Effects of HGF gene polymorphisms and protein expression on transhepatic arterial chemotherapeutic embolism efficacy and prognosis in patients with primary liver cancer.

P2860

Q24561588-C64AB966-0C13-43E1-9131-26E4448347C7 Q24683896-94CDC5B9-0D3A-4B89-967F-85EAFF0A43FF Q27008925-7EAD63FB-D9A0-4CD3-B4E2-8925CABD4A5E Q27011423-794AF16A-057D-4045-9632-B19CEBC953EB Q27028079-F7EC7E33-3605-41C8-8C4B-7AB2BF16BC28 Q27304708-C2919C59-106B-4616-84B0-F9B6C2D5A9EA Q27647900-97847721-DD38-4FC8-B12A-8EA0E85D16D3 Q27649203-3D939223-385B-46EC-876A-D4EC6FBEAFA9 Q28209273-4A2B6514-566A-4914-B8AE-DEC0052606FF Q29010479-2DDF19A1-7EBB-42FC-A809-C96DCA9CB6B4 Q30427677-4147E851-FB56-4B99-8957-1D5BA3B22DC7 Q30436756-E28F5D62-6A2A-4FB8-BDBB-51123BD13A57 Q30501481-8354A168-4861-44F7-AC8E-355FB3FA4EFC Q33654173-77BC3F1D-7F63-4CA7-9366-4744E45F82C8 Q34236834-9D20021C-63DC-4BA1-B0BC-09D02B036EC7 Q34398276-352270C6-25EE-45CB-AB3C-0C042626184B Q34588638-5F8CE7CB-99CE-48C1-AEA9-2A3F5CB69EB2 Q34616966-A082FD2D-1B15-40F8-B65F-71EB58B1DB37 Q34837255-FF41373C-C303-4755-A2C5-5A10D19B9CEA Q35551938-CF62757C-D188-4D80-9A7D-234EA3A51BE4 Q35673676-C8720E0A-652E-4084-AAEE-361107BA802F Q35677873-BC73639F-6369-494D-B2E6-06C3C4E3785D Q36075922-37C13B4B-904D-475B-B9DF-9EED8B4852C8 Q36095630-9C535F3E-00DA-45AB-8B48-A87A2F8064B9 Q36411841-4121E5BE-2D93-4CE2-9DA0-1D40744DCF77 Q36501662-06576CD7-1CD8-427E-85B1-4A19949A8CD5 Q36689648-14568AD6-4706-455E-BD1C-23E9C12F047C Q36746959-35752439-E3E9-4FF3-896C-54FFF963E17B Q36764016-0366D1F9-F2D0-4B10-B210-F20919F2720D Q36777999-91701634-8AB5-42CA-BE27-171ECD7A2A76 Q37129915-A1056A18-FD99-442F-A4BE-C43E04CA4F07 Q37138521-6A84101D-6128-4992-8E34-0FBFD36B06AE Q37169357-68FA005D-4C0A-4832-8A39-1143331470BA Q37232416-5A09557E-2CCA-4E7D-9429-C1313C90D769 Q37312433-0FFB7AA3-194D-411C-84AA-A5370E9E2A3B Q37329927-EDD450F5-969F-489B-9F9F-76D73E9081DB Q37331862-C0364E8F-4112-4D8B-90D7-7B753388BA44 Q37523867-9828C820-BB9C-4B6D-96F2-048B35D795EC Q37600270-90204F59-E8F0-4AC1-9429-3EFFC06ED2F2 Q37650102-E95B7230-32CD-4183-AFDC-EC8961CD6174

P2860

Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models

http://www.wikidata.org/entity/Q24629814

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Neutralizing monoclonal antibo ...... umor activity in animal models

@ast

Neutralizing monoclonal antibo ...... umor activity in animal models

@en

Neutralizing monoclonal antibo ...... umor activity in animal models

@nl

type

label

Neutralizing monoclonal antibo ...... umor activity in animal models

@ast

Neutralizing monoclonal antibo ...... umor activity in animal models

@en

Neutralizing monoclonal antibo ...... umor activity in animal models

@nl

prefLabel

Neutralizing monoclonal antibo ...... umor activity in animal models

@ast

Neutralizing monoclonal antibo ...... umor activity in animal models

@en

Neutralizing monoclonal antibo ...... umor activity in animal models

@nl

P1433

Q24629814-502FAD73-C087-4D7C-9B60-58668CE1DF24

P1476

Q24629814-1019F7DC-FAD0-4CCC-9746-5AFCA8881887

P2093

Q24629814-0A8E7F37-EC04-4A08-8D26-6FB988E27EBF

Q24629814-0C94651B-F93C-43DC-BEF4-93329824FB4F

Q24629814-13995AE2-93FA-4D6C-A161-2177A9A1D675

Q24629814-2C120E94-5DF9-4881-A45A-E7C47EA85159

Q24629814-2C2DE545-5EE6-45DF-9014-585B15AF9EB3

Q24629814-8226E1B4-E59E-4A87-9D76-52D9FB74E060

Q24629814-8735F9A3-FDB0-473C-B6D7-0542FFCA263C

Q24629814-903FB1BB-8B9F-4722-8E5D-DB6528781D6F

P2860

Q24629814-044D07C0-9B46-4247-AA0E-910206AB3167

Q24629814-0A2C2BAA-6F57-432D-BF82-8673245FB68F

Q24629814-0C840F55-A121-47D5-B04F-23C488C2CFED

Q24629814-11D4F5BC-31EC-4F9F-A247-050053A8B6CE

Q24629814-239B3519-B9F4-4126-A69D-3EE4305FF970

Q24629814-33555797-3F7F-4977-8E19-11058DAED558

Q24629814-42E70670-68A1-4881-915D-1A7BB9355848

Q24629814-446A89F7-D587-4BEF-AC4E-5DB459CDADB9

Q24629814-4864471D-157F-45D2-AFD1-BFEFFFB81B5B

Q24629814-5D6E717D-CD81-4C24-9C99-B4B32AF6B871

P304

Q24629814-D8BAE0AB-B712-4846-9DD5-74FAD729206E

P31

Q24629814-81CB16CA-FEEF-4543-ADFA-716E5D3E3AF8

P356

Q24629814-A42BE3FB-A513-487C-9DA6-C2F857009EA7

P407

Q24629814-921F9251-8A31-4883-8AA6-48F6C9C87B42

P433

Q24629814-36E8F64A-9898-4E36-81C3-E7D9CB3BCC7B

P478

Q24629814-49A2EE18-D521-4245-89F2-0B04C17E1EA9

P577

Q24629814-7531960A-604F-40C3-A80D-2D242358F17E

P5875

Q24629814-B8D49E25-673A-4F68-9035-94BF543AB0CD

P698

Q24629814-C906426F-2C06-4619-811A-8586F7F7CC2B

P921

Q24629814-2E75A0A7-FD75-41D7-AAB3-9DACAB252374

P932

Q24629814-D0FF8F94-8909-4E74-8758-AE1D7D47E4E4

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Neutralizing monoclonal antibo ...... umor activity in animal models

@en

P2093

B Cao

http://www.w3.org/2001/XMLSchema#string

E J Kort

http://www.w3.org/2001/XMLSchema#string

G F Vande Woude

http://www.w3.org/2001/XMLSchema#string

L M Wang

http://www.w3.org/2001/XMLSchema#string

M Oskarsson

http://www.w3.org/2001/XMLSchema#string

P Zhao

http://www.w3.org/2001/XMLSchema#string

R J Fisher

http://www.w3.org/2001/XMLSchema#string

Y Su

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase

Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor

Vascular endothelial growth factor is a secreted angiogenic mitogen

The met proto-oncogene receptor and lumen formation.

New paradigms for the treatment of cancer: the role of anti-angiogenesis agents.

Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation.

Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor

Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2.

P304

7443-8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.131200498

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-06-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11924445

http://www.w3.org/2001/XMLSchema#string

P698

11416216

http://www.w3.org/2001/XMLSchema#string

P921

P932

34688

http://www.w3.org/2001/XMLSchema#string